SUBSCRIBE
SUBSCRIBE
News   Policy

GlaxoSmithKline Sues Partner XenoPort, Inc. Over Marketing Allegations on RLS Drug

February 24, 2012 | 
1 min read
GlaxoSmithKline (NYSE:GSK) is pushing back against drug partner XenoPort (NASDAQ:XNPT) over claims that GSK is not doing enough to sell the restless-leg syndrome treatment they jointly developed.
Legal Europe
GSK
MORE ON THIS TOPIC
Emblem design for airlines, airplane tickets, travel agencies. Airplane icon and destination arrow. Flags of the USA and Great Britain. 3D rendering
Huntington’s disease
UniQure eyes UK approval for embattled Huntington’s gene therapy after FDA quarrel
April 30, 2026
 · 
2 min read
 · 
Heather McKenzie
Business concept illustration of a businessman sitting contemplating on fallen arrow sign, bankruptcy, failure in business concept
Company closure
6 biotechs that called it quits in Q1
April 30, 2026
 · 
6 min read
 · 
Angela Gabriel
Recovering losses, effective economic measures to help alleviate inflation or economic crisis resulting in the collapse of the business economy or stock market, helping hands to catch gold coins rolling down a tilted cliff
Patents
Pfizer settles with generic drugmakers to protect blockbuster drug until 2031
April 29, 2026
 · 
2 min read
 · 
Nick Paul Taylor
man pulling each of the opposite ends of a rope in black and white, on a blue background with some blank space on top
Pancreatic cancer
Revolution levels legal threat on Erasca as pancreatic cancer rivalry heats up
April 28, 2026
 · 
3 min read
 · 
Tristan Manalac